文献速递临床试验与 GCP基础与转化研究

特定氨基酸复合配方在住院神经性厌食症患者中的疗效与耐受性:随机对照试验研究方案

Efficacy and tolerability of a specific blend of amino acids in patients with anorexia nervosa treated in a hospital setting: study protocol for a randomized controlled trial.
PubMed 文献 · Trials · 2023-02-09

本研究为一项13周随机双盲安慰剂对照试验方案,计划纳入92例16-50岁正在接受强化住院及日间医院治疗的神经性厌食症患者,评估补充必需氨基酸(EAA)与三羧酸(TCA)循环中间体(柠檬酸、苹果酸、琥珀酸)对瘦体重变化及其他躯体与心理结局的疗效。主要目的是评估补充对体重恢复过程中瘦体重变化的影响,次要目的包括体能、体重恢复、厌食症及一般精神病理和心理社会功能损害。

要点

  • 13周随机双盲安慰剂对照试验,计划招募92例16-50岁神经性厌食症患者。
  • 干预为EAA与TCA循环中间体(柠檬酸、苹果酸、琥珀酸)复合补充剂或安慰剂。
  • 主要结局为体重恢复过程中瘦体重的变化,双盲评估在基线(T0)和13周治疗结束时(T1)进行。

核心结论

  • 研究结果将告知研究人员和临床医生,补充EAA与TCA循环中间体混合物是否能改善接受强化专科治疗并恢复体重的神经性厌食症患者瘦体重的增加及其他重要躯体和心理结局。

研究设计与样本

  • 13周随机、双盲、安慰剂对照研究,患者入院接受强化住院及日间医院进食障碍治疗时随机分配至EAA与TCA循环中间体(柠檬酸、苹果酸、琥珀酸)复合混合物补充组或安慰剂组。
  • 计划从进食障碍强化专科治疗中招募92例16-50岁神经性厌食症患者,在基线(T0)和13周治疗结束(T1)进行双盲评估。
  • 试验注册号NCT05290285,注册日期2022年3月22日。

关键数值与推荐

  • 主要目的为评估补充EAA与TCA中间体对接受进食障碍专科治疗的神经性厌食症患者体重恢复过程中瘦体重变化的疗效。
  • 次要目的为评估膳食补充对体能、体重恢复、神经性厌食症及一般精神病理改变和心理社会功能损害的影响。

临床怎么用

  • 原文未据此给出推荐。

局限性

  • 原文未报告局限性。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

BACKGROUND: Specific blends of essential amino acids (EAA) containing a high percentage of branched-chain amino acids preserves mitochondrial metabolism and higher physical resistance in elderly mice, increasing their survival and improving physical performance and cognitive functions in malnourished elderly patients. However, no study has been yet done on patients with anorexia nervosa (AN) who regain weight with specialized intensive treatment. The present study aims to evaluate the efficacy of supplementation with EAA on the change in lean body mass (LBM) and other physical and psychological outcomes in patients with AN who are undergoing specialist treatment for eating disorders. METHODS: This is a 13-week randomized, double-blind, placebo-controlled study. Patients will be randomized to either a mixture of a complex blend of EAA and intermediates of the tricarboxylic acid (TCA) cycle (citrate, malate, succinate) supplementation (or placebo) upon admission at the intensive residential and day-hospital treatment for eating disorders. Ninety-two participants with AN aged 16-50 years will be recruited from a specialized intensive treatment of eating disorders. Double-blind assessment will be conducted at baseline (T0) and the end of the 13 weeks of treatment (T1). The study's primary aim is to evaluate the efficacy of supplementation with EAA and TCA intermediates on the change in lean body mass (LBM) with weight restoration in patients with AN who are undergoing specialist treatment for eating disorders. The secondary aims of the study are to assess the effect of dietary supplementation on physical fitness, weight restoration, modification of AN and general psychopathology, and psychosocial impairment. DISCUSSION: The study's results will inform researchers and clinicians on whether supplementing a mixture of EAA and TCA cycle intermediates will improve the increase of LBM and other important physical and psychological outcomes in patients with AN who regain weight with specialized intensive treatment. TRIAL REGISTRATION: NCT, NCT05290285. Registered on 22 March 2022.

来源:Trials,查看原文。版权归原作者所有。

引用

  1. Dalle Grave R, Calugi S, Ruocco C, et al. Efficacy and tolerability of a specific blend of amino acids in patients with anorexia nervosa treated in a hospital setting: study protocol for a randomized controlled trial. Trials. 2023. PMID: 36759873. doi:10.1186/s13063-023-07120-7

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。